IFNA1 and hepatocellular carcinoma: Over the last decade, advancements in antiviral agents, including IFN, NAs, and DAAs, have enabled sustained viral suppression or cure in most chronic HBV/HCV patients, significantly impacting HCC prevention (Table 3).